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Background and objective: Hormonal therapy is the treatment of choice in most infants 
with infantile spasms (IS). Intramuscular adrenocorticotropic hormone (ACTH) has 
historically been the treatment of choice, however, its usage is complicated by unavailability 
and financial constraints, even more so in resource limited settings. Our institution has used 
high dose prednisone as the first-line hormonal treatment of infantile spasms since 2006. In 
this study we investigated the efficacy and safety of high dose oral prednisone. In addition, 
we describe the most common causes of IS in our setting.    
 
Methods: Medical records of infants who presented to Tygerberg Hospital with IS and who 
were treated with high-dose oral prednisone (4mg/kg/day), from September 2012 through 
August 2016, were reviewed. Electro-clinical response was defined as clinical spasm-
freedom and resolution of hypsarrythmia within two weeks of initiation of therapy.  
 
Results: Over the 4-year period, 50 children with new-onset IS were treated. The mean 
duration of epileptic spasms prior to initiation of treatment was 15.4 days (range 7.64-23.176 
days) and the mean age of diagnosis was 22.83 weeks (range 19.19-26.47 weeks). The 
majority of infants (78%) exhibited developmental delay prior to the onset of spasms. 
Hypoxic ischemic encephalopathy and white matter injury of prematurity, were the most 
common etiologies. Electro-clinical response occurred in 32 (64%) of infants within two 
weeks of the onset of treatment. No major side effects were encountered during the 
treatment period.   
 
Conclusion: Our results continue to demonstrate that high dose oral prednisone is very 
effective for the treatment of new-onset infantile spasms, with no major adverse effects. Oral 
prednisone represents a less expensive, readily available alternative to ACTH injections, 
especially in resource-constrained settings. A significant proportion of IS cases can be 
attributed to potentially preventable etiologies such as hypoxic ischemic encephalopathy, 






Agtergrond: Hormonale terapie is die behandeling van keuse vir die meeste kinders met 
infantiele spasmas (IS). Intramuskulêre adrenokortikotrofiese hormoon (AKTH) is histories 
die behandeling van keuse, maar die gebruik daarvan word gekompliseer deur 
ontoereikenheid and finsiële beperkings veral in beperkte hulpbronne instansies.  Hoë dosis 
prednisoon word as eerste linie hormonale terapie vir IS by Tygerberg Hospitaal gebruik.  In 
hierdie studie word die effektiwiteit en veiligheid van hoë dosis prednisoon ondersoek.  
Verder, word ook die mees algemene oorsake van IS, by ons instansie, beskryf. 
 
Metodes: Die mediese rekords van kinders wat by Tygerberg Hospitaal presenteer het met 
IS en met hoë dosis orale prednisoon (4mg/kg/dag), vanaf September 2012 tot en met 
Augustus 2016 behandel is, was na gegaan. Elektro-kliniese respons was gedefinieer as 
klinies spasma vryheid en resolusie van hipsaritmië binne twee weke vanaf die begin van 
behandeling.  
 
Resultate: ‘n Totaal van 50 kinders, oor ‘n 4 jaar periode, was met nuwe aankoms IS by 
Tygerberg Hospitaal behandel.  Die gemiddelde duur van spasmas voor die begin van 
behandeling was 15.4 dae (omvang 7.64-23.176 dae) en die gemiddelde ouderdom met 
diagnose was 22.83 weke (omvang 19.19-26.47 weke). Die meerderheid van kinders (78%) 
het ontwikkelingsagterstand getoon voor die begin van spasmas. Hipoksiese isgemiese 
enkefelopatie en witstof besering van premaruteit was die mees algemeenste oorsake. 
Elektro-kliniese respons was behaal in 32 (64%) van kinders binne twee weke van die 
aanvang van behandeling. Geen nadelige effekte was aangemeld tydens die 
behandelingsperiode.  
 
Gevolgtrekking: Die resultate demonstreer dat hoë dosis prednisoon ‘n baie effektiewe 
behandeling vir nuwe aankoms IS is, met geen noemenswaardige nadelige effekte nie. Orale 
prednisoon is ‘n meer bekostigbare, maklik verkrygbare alternatief tot AKTH intramuskulêre 
inspuitings, veral by ‘n beperkte-hulpbron instelling.  ‘n Groot hoeveelheid van IS gevalle het 
potensieël ‘n voorkombare etiologie, soos hipoksiese isgemiese enkefelopatie, witstof 
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Infantile spasms (IS) are a rare seizure disorder that primarily occurs during the first year of 
life, especially between the third and eighth months. The syndrome of IS consists of a 
constellation of myoclonic-like seizures, whose electroencephalogram (EEG) pattern is that 
of hypsarrhythmia, a disorganized high-voltage pattern with no normal background. The triad 
of spasms, developmental arrest or regression and hypsarrhythmia is known as West 
Syndrome.  
1.2 Problem Statement 
 
The etiology of IS is highly varied and includes perinatal brain injuries, postnatal infections, 
neurocutaneous syndromes, cerebral malformations and trauma. Few studies have 
investigated the causes of IS in infants residing in resource poor countries. We postulate that 
the greatest proportion of cases in our setting will be due to perinatal factors [hypoxic 
ischemic encephalopathy (HIE) and white matter injury of prematurity]. 
 
Management of infants with IS in resource-limited settings is constrained by delay in 
diagnosis and potentially the high cost of treatment. The optimal treatment of IS is unclear 
but many studies advocate hormonal treatment (prednisolone or ACTH). A 2008 Cochrane 
review suggested that hormonal treatment was better that Vigabatrine. Vigabatrin and ACTH 
are expensive and not readily available in many parts of South Africa. Oral corticosteroids 
are a logical, less expensive alternative and the efficacy of high dose prednisolone 
4mg/kg/day is supported by the findings of the United Kingdom Infantile Spasms Study 
(UKISS). Prednisone is on the essential drug list (EDL) for South African public hospitals and 
therefore readily available at all health care levels. The aim of the study was to investigate 
the efficacy and safety of high dose (4 mg/kg/day) prednisone in a consecutive cohort of 
infants with IS residing in the Western Cape province of South Africa. We postulate that the 








Infantile spasms occurs in all ethnic groups. Some studies have found that boys and girls are 
affected equally, while others suggest that boys are somewhat more likely to be affected.1 A 
positive family history of IS occurs in 1-7% of cases, suggesting a genetic susceptibility. The 
evaluation of an infant with suspected IS should include an EEG and a search for treatable 
disorders and precipitating factors. Magnetic resonance imaging (MRI) is the special 
investigation modality with the highest diagnostic yield as it may identify etiological causes 
such as cortical malformations, hypoxic ischemic encephalopathy (HIE), periventricular 




Previously, the International League against Epilepsy (ILAE) classified IS according to the 
underlying etiology as follows:  
 
1. Idiopathic: Patients with normal development at onset, normal examination and 
neuroimaging, and hypsarrhythmia EEG pattern without focal epileptiform 
abnormalities.  
2. Symptomatic: evidence of pre-existing brain insults due to antenatal/perinatal or 
postnatal causes, including brain malformations, hypoxic ischemic encephalopathy 
(HIE), periventricular leukomalacia (PVL), infections, or inborn errors of metabolism. 
3. Cryptogenic: Presumed underlying causes due to neurological or developmental 
abnormality, but investigations are inconclusive. 
 
 The ILAE revised classification and terminology of seizures and epilepsies, published in 
2010, designated West syndrome as an electroclinical syndrome with onset in infancy and 
epileptic spasms as a type of seizure. It furthermore recommended that the causes of IS 
should instead be classified as:  
 
1. Genetic (examples include trisomy 21, and ARX and CDKL5 mutations) 
2. Structural/Metabolic 







The proportion of etiological categories of IS varies among different studies. In a prospective, 
multicentre study on the evaluation of new-onset IS from the National Infantile Spasms 
Consortium, 251 infants were enrolled, and a cause was identified in 161 patients (64%).2 
The most commonly identified causes were structural acquired (22%), genetic (14%), 
structural congenital (11%), genetic structural (10%), metabolic (5%) and infection (2%). 
Clinical evaluation with MRI provided a specific diagnosis in 55% of the infants.  
 
The critical time of the insult typically occurs in the prenatal, perinatal or postnatal period. 
Pre- or perinatal complications account for the greatest proportion of cases (45.6%).2 Down 
syndrome was the most common genetic cause (42% of purely genetic etiologies). Tuberous 
sclerosis accounted for nearly half of genetic-structural etiologies.2 About 10% of those with 




Infantile spasms are notoriously difficult to treat, as it often is unresponsive to conventional 
anti-epileptics. Most specialist centers advocate hormonal treatment (adrenocorticotrophic 
hormone (ACTH) and prednisolone). The 2004 United Kingdom Infantile Spasms Study 
(UKISS)4 assessed the relative efficacy of hormonal treatment (prednisolone or ACTH) and 
vigabatrin in a multi-centre, randomized-controlled trail in 150 hospitals in the UK. The 
primary study outcome was cessation of spasms within 2 weeks. Minimum doses were 
vigabatrin 100mg/kg per day, oral prednisolone 4 mg/kg per day, or intramuscular 
tetracosactide depot 0.5mg (40 IU) on alternative days. Analysis was by intention to treat. 
Hormonal therapy was successful in 73% of infants after 2 weeks compared with vigabatrin 
in 54%. Adverse effects were reported in 55% of infants on hormonal treatment and 54% of 
infants on vigabatrin (i.e. no statistical difference) No deaths were recorded. This study and a 
subsequent Cochrane review recommended that hormonal therapy was more effective than 
vigabatrin in the short term.5 
 
Two earlier studies comparing oral 2mg/kg/day prednisone and intramuscular 150U/m2/day 
ACTH reported that oral corticosteroids were less effective.6,7 However, in the UKISS, a 
higher dose 4-6 mg/kg/day oral prednisolone was found to be equivalent to synthetic ACTH 
(70% vs. 76% spasm freedom after 14 days, respectively).4 The effectiveness of a higher 
dose of prednisolone was also illustrated in subsequent studies8,9 and oral prednisolone had 
fewer adverse effects and was less expensive than ACTH.9 Hussain et al showed that 63% 
of patients responded completely to prednisolone 8mg/kg/day8. The underlying cause seems 
to influence choice of treatment as well, since Vigabatrin has proven to be particularly 





In resource-constrained settings, availability and affordability of drugs are of critical 
importance. ACTH is expensive [R 345.01 per vial (1mg/1ml)], not freely available, not 
without adverse effects and has to be administered by intramuscular route. In contrast, 
prednisone (R 14.96 per 100, 5 mg tablets) is less expensive, easily available (on the EDL) 
and can be given orally.  
 
Raga SV et al. conducted a systemic review of the literature to access the quality of evidence 
of prednisone and prednisolone for the management of epileptic spasms.11 The study 
concluded that there is class III evidence (level C recommendation) to support the efficacy of 
oral prednisone compared to class IV evidence for ACTH. Accordingly, they then proposed a 
treatment algorithm based on the availability of vigabatrin and ACTH. Prednisone 
4mg/kg/day was recommended in settings were either vigabatrin was available but ACTH not 
available or both ACTH and vigabatrin were unavailable. Additional randomized-controlled 
trials (RCT) were recommended to compare oral corticosteroids to ACTH and to determine 
the optimal dose, comparison efficacy, as well as long-term studies looking at the 
neurodevelopmental outcomes of these groups.  
 
More recently, the results of a multicentre open-label randomized trial was published which 
explored whether combined therapy would be more effective than hormonal therapy in 
isolation.12 The authors found hormonal therapy with vigabatrin significantly more effective at 
stopping IS than hormonal therapy alone. However, combination therapy did not result in 




Chapter 3: Method 
3.1 Aim and objectives 
 
The aim of the study was to determine the efficacy and safety of high dose oral prednisone 
4mg/kg/day in the treatment of infants with IS.  
 
Secondary objectives were: 
1. To describe the etiology of infantile spasms  
2. To determine whether the underlying etiology influences response to therapy  
3. To describe whether the baseline EEG background pattern influences response to 
therapy 
4. To describe the yield of special investigations (MRI) in children with IS   
 
3.2 Research design 
 
This was a retrospective analysis of all children presenting with infantile spasms to the 
paediatric neurology service at Tygerberg Hospital (TH) over a four-year period (September 
2012 till August 2016.)  
 
3.3 Study site  
 
The paediatric wards are situated in the G-Block of Tygerberg Hospital, the academic 
training hospital of the Stellenbosch University. This hospital’s paediatric wards serves the 
immediate surrounding areas, providing primary and secondary health care to children, as 
well as tertiary care to all paediatric patients in Metro East district of Cape Town, as well as 
the northern and eastern rural districts of the Western Cape. Paediatric patients with epilepsy 
are diagnosed and managed in ward G9, a tertiary paediatric neurology ward. Epilepsy is 
one of the most common presenting complaints in children referred to the ward.  
 
3.4 Study Population and Sampling 
 
The target population was all children with suspected IS referred to the tertiary paediatric 
neurology service at TH. All subjects underwent baseline EEG recording to ascertain the 





Inclusion criteria: All infants between the ages of 3 months and 1 year with IS were 
included.   
Exclusion criteria: Inadequate clinical information. 
  
Study participants were systematically identified from the neurological ward and EEG 
database at TH. 
 
3.5 Operational definitions 
 
 For the purpose of the study, the following definitions was used:  
• Sex: Male or Female  
• Low birth weight was defined as a birth weight less than 2,5 kg 
• Late preterm were defined as infants born between 34 weeks and 0 days and 36 
weeks and 6 days gestational age. Term infants were born at a gestational age > 37 
weeks   
• A 5-minute Apgar score of 7-10 was considered as reassuring, a score of 4-6 as 
moderately abnormal and a score of 0-3 as low in the term and late-term infant 
• Microcephaly was defined as a head circumference which is more than 2 standard 
deviations below mean for gestational age and gender. Marcocephaly was defined as 
a head circumference > 2SD above the mean for gestational age and gender.  
• Neonatal seizures were defined as seizures within the first 28 days of life.  
• Idiopathic IS refers to infants with normal development at onset, normal examination 
and neuroimaging, and hypsarrhythmia EEG pattern without focal epileptiform 
abnormalities.  
• Symptomatic IS refers to infants with evidence of pre-existing brain insult due to 
antenatal/perinatal or postnatal causes, including brain malformations, hypoxic 
ischemic encephalopathy (HIE), periventricular leukomalacia (PVL), infections, or 
inborn errors of metabolism. 
• Satisfactory response (treatment response): Complete cessation of spasms (both 
EEG and clinical responses) within 2 weeks of therapy.  
 
3.6 TH IS investigation and treatment algorithm  
 
Infants were evaluated by detailed history, physical examination and pertinent investigations 
were carried out. Patients were diagnosed with IS when they presented with characteristic 




hyppsarrythmia or modified hyppsarrythmia). MRI/CT was performed in all children. Plasma 
amino acids, ammonia, lactate, pyruvate, urine organic acids, acid-base analysis and HIV-
ELISA testing were performed where clinically indicated. Co-morbid conditions including 
visual and hearing problems were assessed and recorded. Tuberculin skin testing and chest 
radiography were requested in infants with tuberculosis risk factors. Molecular testing is 
locally available for mutations in the ARX gene. Indications for ARX mutation analysis 
include: X-linked lissencephaly with abnormal genitalia (XLAG), severe hydrocephalus, 
Proud syndrome (agenesis of the corpus callosum with abnormal genitalia), polymicrogyria 
with periventricular heterotopia and the clinical presence of dystonia. Early infantile epilepsy 
panel testing (invitae) was not available at the time of the study.   
 
First-line therapy for all infants with IS consists of high dose (4 mg/kg/day) oral prednisone. A 
clinical response to treatment constituted a complete cessation of epileptic spasms and 
normalization of the EEG background within 2 weeks of therapy. For those children in whom 
the spasms were successfully treated, after 2 weeks of this dose, prednisone was then 
reduced gradually over a 2 week period. If spasms did not improve after 1 week, 
intramuscular ACTH (40 IU) was introduced. Vigabatrin was reserved for the treatment of 
TSC-associated IS. Prior to treatment, serum electrolytes, glucose and blood pressure were 
measured. The presence of complications such as gastrointestinal hemorrhage, herpes 
simplex virus reactivation, tuberculosis reactivation and hypertension were noted. 
Seizure (spasm) frequency was monitored by the nursing staff and caregivers who 
maintained a daily seizure diary. Side effects such as hypertension, irritability and glycosuria 
were noted. 
     
3.7 Data collection 
 
Data was primarily sourced from the admission book and discharge-summaries in the G9 
paediatric neurology ward. TH uses an Open Text Enterprise Content Management (ECM) 
system where routine health information is captured. Medical staff, employed by TH, has 
password-protected access to view patient folders electronically. Documents and clinical 
information were obtained from ECM as well as data reviewed on the EEG reporting 
database using the unique hospital number.  
 
Each patient enrolled in the study was assigned a unique patient identifier number. A paper-
based case report form (CRF) was used to collect the data from the radiology database and 
clinical records. This data was then entered into an electronic database. Patient names, 




The data collected on the proforma included gender, age of onset with IS, age at diagnosis 
and initiation of treatment, type of spasms (flexor, extensor or others), etiological factors 
(perinatal events, mode of delivery, gestational age, presence of a neonatal encephalopathy 
and seizures, developmental delay, other postnatal complications (hypoglycemia), 
neurocutaneous syndrome, MRI and EEG findings as well as type of treatment and 
response.  
 
All EEG’s were reported by 2 paediatric neurologists (RVT and RS). For the study, the EEG’s 
were classified into 3 types: type 1) Multi (focal) epileptic discharges < 50% of the non-REM 
EEG recording time, type 2) Bihemispherical epileptic discharges > 50% of the non-REM 
recording time with abnormal background activity (modified hypsarrythmia)  and type 3) 90-
100% irregular bi-hemispheric sharp wave activities in the non-REM EEG (hypsarrythmia). 
 
3.8 Data analysis 
 
This was a retrospective study, therefore descriptive analysis was performed. Data was 
analyzed using SPSS version 25 (SPSS Inc, Chicago, IL, USA). Descriptive statistics were 
used to analyse demographic data and outcome. Numerical variables were summarized 
using means and standard deviations, if the data was normally distributed. Medians and 
interquartile range were used when the data distribution was skewed. Categorical variables 




Data was retrospectively analysed which may have impacted on the quality of the collected 
data. Limited study numbers did not allow extensive correlation testing. Sophisticated genetic 
testing was not available and therefore the percentages of genetic cases were most likely 




A request for a waiver of individual informed consent was requested and obtained from the 
Health Research Ethics Committee (HREC) at Stellenbosch University, as this was a 
retrospective review of routinely-collected data with minimal risk.  Consent from the CEO of 
Tygerberg Hospital, as the custodian of this data, was obtained.  
 
Data was extracted from the ward admission registers, patient records and the EEG 




steps were undertaken: 1) data entered in electronic databases was password protected b) 
data was only communicated in anonymous form from the clinicians via encrypted data 
transfer for analysis purposes c) hard copies of the data were stored in a safe in a locked 
room. 
 
This study was approved by the HREC of Stellenbosch University (S15/05/118) 
 
The study findings are of importance as it may inform physicians of the efficacy and safety of 
high dose oral prednisone for the treatment of infants with IS in resource-constrained 
settings.     
 
Chapter 4: Results 
 
A total of 74 patients with IS were registered during the study period and 50 (67%) fulfilled 
the eligibility criteria. The clinical profile of the study population is shown in table 1. Males 
were predominant 58% (n=29). The mean duration of epileptic spasms prior to initiation of 
treatments was 15.4 days (range 1-168 days) and the mean age of diagnosis was 22.83 
weeks (range 4-64 weeks). The majority of infants (78%) exhibited developmental delay prior 
to the onset of spasms.  
 
Table 2 illustrates the etiological categories and precise etiologies of the study population. 
Structural-acquired causes represented by far the largest etiological category followed by 
“unknown” and genetic structural. The low percentage of pure genetic causes can be 
attributed to limited genetic diagnostic testing available. Hypoxic-ischaemic encephalopathy 
(HIE) and white matter injury of prematurity represented the most common etiologies.The 
diagnostic profile of children with IS is shown in table 3. Hypsarrythmia (62%) was the most 
common EEG finding. MRI was performed in all infants; it was normal in 28% of cases. 
Potentially preventable causes such as HIE, PVL and hypoglycemic encephalopathy were 
common MRI findings. Cerebral malformations were identified in 5 (10%) of cases and 
included such disorders as absence of the corpus callosum (Aicardi syndrome), open-lip 
schizencephaly, semi-lobar holoproscencephaly, perisylvian polymicrogyria and 
lissencephaly with band heterotopia. Metabolic workup was carried out in 10 (20%) of the 
infants. No inborn error of metabolism was identified in any of the cases.  
 
Table 4 illustrates the therapeutic responses in the infants with IS. The satisfactory response 
rate of high dose oral prednisone in all the study subjects was 64% (32 out of 50 infants); 
60% of the idiopathic IS cases and 64% of symptomatic cases responded favorably. 




different etiological categories. Of interest was that none of the IS infants with genetic 
structural brain anomalies demonstrated a satisfactory high dose prednisone treatment 
response. 
 
None of the children developed hypertension that was severe enough to warrant cessation of 
therapy and addition of hypertensive therapy. No major adverse events such as 



































Chapter 5: Discussion – conclusion and recommendations 
 
This study highlights the clinical profile and response to oral prednisone in children with IS at 
a tertiary center in the Western Cape Province of South Africa. We observed a slight male 
predominance (58%) in keeping with the 6:4 male-female ratio reported in the literature.13 
Male predominance is not a consistent finding in the literature. In this study it may reflect the 
predominance of males in the referral population. Alternatively, it may be due to the 
increasing vulnerability of HIE or neonatal hypoglycemia in male infants.14 None of the study 
infants were HIV-infected, which is in keeping with the absence of studies reporting HIV-
infection as a risk factor for IS. 
 
In children with IS, treatment delay (even by 1 week) has been associated with poor long-
term developmental outcomes.15 It is therefore concerning that the mean duration of epileptic 
spasms prior to initiation of treatments in our setting was 15.4 days (range 1-168 days). We 
postulate that the cause of the delays are multif-actorial and are likely related to misdiagnosis 
and diminished access to specialty care. The majority of infants (78%) exhibited 
developmental delay prior to the onset of spasms and a significant proportion of these cases 
could be attributed to potentially preventable etiologies such as HIE, white matter injury of 
prematurity and hypoglycemic encephalopathy.  Improved obstetric and neonatal care could 
potentially lower the prevalence of IS in our setting. 
 
MRI represents the diagnostic modality of choice in the investigation of infants with IS. In our 
study, an underlying cause was identified in 62% of cases after adequate history-taking and 
physical examination. A genetic etiology was only identified in 8% of cases. The low 
percentage of pure genetic causes can be attributed to limited genetic diagnostic testing 
available in our resource constrained setting. A study conducted by the National Infantile 
Spasms Consortium of the United States reported a diagnostic yield of 11% when 
microarray-based comparative genomic hybridisation (aCGH) was instituted and 31% when 
early infantile epilepsy gene panels were used.16 
 
Metabolic workup was carried out in 10 (20%) of the infants. No inborn error of metabolism 
was identified in any of the cases. Metabolic etiologies have been reported to be rare. 
Conditions that warrant exclusion include Pyridoxine dependency, biotinidase deficiency, 
PEHO syndrome, mitochondrial disorders, molybdenum co-factor deficiency and non-ketotic 
hyperglycinaemia. The reported response rate of high dose oral prednisone in other reported 
observational studies vary from 60-80%.8,17,18 In our study, the satisfactory overall response 
rate was 64% (32 out of 50 infants); 60% of the idiopathic IS cases and 64% of symptomatic 




high dose prednisone in the different etiological categories. Of interest was that none of the 
IS infants with genetic structural brain anomalies demonstrated a satisfactory high dose 
prednisone treatment response. This warrants further investigation. No major adverse events 
such as gastrointestinal bleeding or herpes simplex/TB reactivation were noted. 
 
Our results continue to demonstrate that high dose oral prednisone is very effective for the 
treatment of new-onset infantile spasms, with no major adverse effects. Oral prednisone 
represents a less expensive, readily available alternative to ACTH injections, especially in 
resource-limited settings. Our recommendation would be to use 4mg/kg/day oral prednisone 
as first line treatment for IS, in a limited-resource setting, and intramuscular ACTH (40IU) 
should be introduced for those that do not respond after 1 week of treatment with oral 
prednisone. Vigabatrin should be reserved for the treatment of TSC-associated IS. 
 
A significant proportion of IS cases can be attributed to potentially preventable etiologies 
such as HIE, white matter injury of prematurity and hypoglycemic encephalopathy. Optimal 
obstetric and neonatal care could potentially lower the incidence of IS dramatically, thereby 
reducing the high morbidity associated with IS. Further studies should be done to compare 
the clinical response, optimal dose and long-term neurodevelopmental outcomes to high 
dose oral prednisone vs ACTH in the treatment of IS. A double-blind randomized control trial 




















 Table 1: Clinical profile of the infants with infantile spasms (N=50) 
 
AED= anti-epileptic drugs, IS= infantile spasms, SD= standard deviation
Variable n/N (%) 
Male gender  29/50 (58) 
Birth weight 
Low birth weight (< 2.5 kg) 






Late preterm (34 -36 weeks 5 days) 





5-minute Apgar score 
Reassuring > 7 
Moderately abnormal 4-6 























Neonatal seizures present 16/50 (32) 
Prior AED prior to onset of IS 20/50 (40) 
Developmental delay prior to onset of spasms 39/50 (78) 
 Mean (SD) 
Duration of spasms prior to treatment (days) 15.40 (26.44) 




Table 2: Etiological categories and specific etiologies of the infants with infantile 
spasms (N=50) 
 
Etiological categories  n/N (%) 
Genetic 4/50 (8) 
Genetic structural 8/50 (16) 
Structural congenital 3/50 (6) 
Structural acquired 20/50 (40) 
Unknown 15/50 (30) 
Specific etiology  
Hypoxic ischemic encephalopathy 7/50 (14) 
White matter injury of prematurity  6/50 (12) 
Hypoglycemic encephalopathy 2/50(4) 
Tuberous sclerosis 5/50 (10) 
Congenital brain malformation 5/50 (10) 
Perinatal stroke 1/50 (2) 
Hemorrhage 2/50 (4) 
Post-meningitic squelae 0 
Inborn errors of metabolism 0 
Neurofibromatosis  1/50 (2) 

















Table 3: Diagnostic profile of infants with infantile spasms (N=50) 
 
Special investigations n/N (%) 
Electroencephalogram  











WM injury of prematurity (PVL, IVH) 

















Metabolic work up 0  
 
EEG= electroencephalogram, PVL= periventricular leukomalacia, IVH= intraventricular haemorrhage, 































3 4 0 13 12 
Unsatisfactor
y response  
















Case report form (CRF) 
 
Personal identifier  
Date of birth   
Folder number  
Gender: Male Female  
Antenatal problems  
Maternal substance abuse  
Birth weight: VLBW LBW NBW  
Gestational age: preterm, late-preterm term  




Head circumference at birth   
Postnatal complications: IVH, HIE (Neonatal 
encephalopathy severity: mild moderate 
severe) Hypoglycemia, sepsis, meningitis 
 
Neonatal seizures: Yes or No  
Seizures before onset of IS Yes or No  
Prior anti-epileptic Rx Yes or No  
Age of onset IS: weeks  
Duration from onset of spasms  
(as observed by caregiver) and 
diagnosis/treatment (days)  
 
Baseline EEG:   
Etiology: genetic or structural metabolic or 
unknown 
 
Genetic testing: chromosomes  
ARX mutation & others 
 
MRI findings: Specify findings  
Metabolic testing findings (normal/abnormal)  
1st line regimen Prednisone Dose prednisone 
mg/kg Responder Yes No 
 
2nd line regimen: Required  IM ACTH 
Responder Yes No     
 
Adverse effects on treatment:  
Hypertension, hypernatremia, hypokalemia, 
weight gain, edema  
infection, others 
 
Spasms free after 2 weeks    
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